A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.35 USD -3.57% Market Closed
Market Cap: 48.9m USD

EV/EBITDA
Enterprise Value to EBITDA

-2.3
Current
-2.8
Median
3.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.3
=
Enterprise Value
95m USD
/
EBITDA
-41.1m USD
EBITDA Growth EV/EBITDA to Growth
US
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Average EV/EBITDA: 15.3
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -204 590.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -615.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.9
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A